 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C23H35NO2 |
| Molar mass | 357.538 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tonazocine (WIN-42,156) is anopioidanalgesic of thebenzomorphan family which made it tophase IIclinical trials for the treatment of postoperative pain,[1] but development was apparently ceased and ultimately it was never marketed. Tonazocine is apartial agonist at both themu-opioid anddelta-opioid receptors, but acting more like anantagonist at the former and more like anagonist at the latter.[2][3] It lacks most of theside effects of other opioids such asadverse effects on thecardiovascular system andrespiratory depression, but it can causesedation (although to a lesser degree of typical opioids), and in some patients it may inducehallucinations (probably via binding to and activating theκ-opioid receptor).[4]
| Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| μ-opioid (MOR) |
| ||||
|---|---|---|---|---|---|
| δ-opioid (DOR) |
| ||||
| κ-opioid (KOR) |
| ||||
| Nociceptin (NOP) |
| ||||
| Others |
| ||||
